Our client’s requirement
A Biotech firm based on the US East Coast connected with Excelra to help revolutionize prostate cancer screening. The objective was to enhance the reliability of screening, reducing unnecessary biopsies and associated risks, such as bleeding, infection, and additional healthcare costs.
Our approach
We implemented AI/ML techniques leveraging a new semen sample analysis containing diverse biomarkers. Utilized ensemble learning methodologies including Deep Neural Networks and Gradient Boosted Decision Trees.
